SCHEMBL1616253

SCHEMBL1616253

CNc1cccc2nc(N)c([C@@H]3CCc4ccccc43)cc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 1/20 0.37
IDO1 P14902 1/20 0.35
ADRA1A P35348 1/20 0.34
HTR3A P46098 1/20 0.34
SIGMAR1 Q99720 1/20 0.34
NPC1 O15118 1/20 0.33
LMNA P02545 1/20 0.33
PKM P14618 1/20 0.33
NFKB1 P19838 1/20 0.33
RAB9A P51151 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
GBA1 P04062 1/20 0.33
CYP11B2 P19099 1/20 0.33
CD38 P28907 2/20 0.32
ADORA2A P29274 1/20 0.32
GID4 Q8IVV7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2242402 0.85 NPY5R (0.35) CA1CA2CD38
SCHEMBL2242767 0.84 KDM4E (0.44) IDO1ADRA1AHTR3ASIGMAR1NPC1
SCHEMBL2244187 0.83 NCF1 (0.34) IDO1ADRA1ACD38
SCHEMBL2242646 0.83 CSF1R (0.34) IDO1ADRA1AGBA1
SCHEMBL2243239 0.82 NCF1 (0.34) IDO1CD38
SCHEMBL4109733 0.73 ADRA1A (0.42) IDO1ADRA1AHTR3ALMNASMN1; SMN2
SCHEMBL3430394 0.73 ADRA1A (0.42) IDO1ADRA1AHTR3ALMNASMN1; SMN2
SCHEMBL2243951 0.71 IDO1 (0.40) IDO1NPC1LMNARAB9ASMN1; SMN2
SCHEMBL2242716 0.71 NQO2 (0.36) ADRA1ANPC1RAB9A
SCHEMBL3844986 0.71 PDPK1 (0.47) PDPK1CA1CA2GBA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7994324-B2 2-aminoquinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2011-08-09 US claimed
US-20090227584-A1 2-AMINOQUINOLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-09-10 US claimed
US-7994324-B2 2-aminoquinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2011-08-09 US disclosed
US-7923561-B2 Quinolines HOFFMANN-LA ROCHE INC. (US) 2011-04-12 US disclosed
US-20090227584-A1 2-AMINOQUINOLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-09-10 US disclosed
US-20080146567-A1 QUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227584-A1 2-AMINOQUINOLINE DERIVATIVES HTR5A, HTR2C, HTR2B PDPK1 1149/4885IDO1 922/4885ADRA1A 150/4885
US-20080146567-A1 QUINOLINES HTR5A, HTR2B, HTR2C PDPK1 1582/4885IDO1 1009/4885ADRA1A 120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.